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ABSTRACT The mechanism via which pneumolysin (PLY), a toxin and major virulence factor of the bacterium Streptococcus
pneumoniae, binds to its putative receptor, cholesterol, is still poorly understood. We present results from a series of biophysical
studies that shed light on the interaction of PLY with cholesterol in solution and in lipid bilayers. PLY lyses cells whose walls
contain cholesterol. Using standard hemolytic assays we have demonstrated that the hemolytic activity of PLY is inhibited by
cholesterol, partially by ergosterol but not by lanosterol and that the functional stoichiometry of the cholesterol-PLY complex is
1:1. Tryptophan (Trp) ﬂuorescence data recorded during PLY-cholesterol titration studies conﬁrm this ratio, reveal a signiﬁcant
blue shift in the Trp ﬂuorescence peak with increasing cholesterol concentrations indicative of increasing nonpolarity in the Trp
environment, consistent with cholesterol binding by the tryptophans, and provide a measure of the afﬁnity of cholesterol binding:
Kd ¼ 400 6 100 nM. Finally, we have performed specular neutron reﬂectivity studies to observe the effect of PLY upon lipid
bilayer structure.
INTRODUCTION
The study of processes leading to eukaryotic membrane
disruption and pore formation is fundamental to gain a
comprehensive understanding of cell lysis resulting from
bacterial toxins. One such group of toxins is the highly ho-
mologous cholesterol-binding (also historically but wrongly
referred to as thiol-activated) bacterial protein toxins (CBTs,
also known as cholesterol-dependent cytotoxins or CDCs)
which are virulence factors of Gram-positive bacteria, and
include pneumolysin (PLY), perfringolysin (PFO), listerio-
lysin (LLO), and streptolysin (SLO) (see Tweten, 1995). PLY
is a 53 kDa hemolytic protein toxin that constitutes one of the
several potential virulence factors produced by Streptococcus
pneumoniae, which causes various human diseases such as
pneumonia, otitis media, meningitis, and bacteremia (Paton
et al., 1993; Canvin et al., 1997).
An atomic structure of PLY is not yet available, although
Kelly and Jedrzejas (2000a) recently reported the successful
crystallization of PLY complexed with a cholesterol analog.
Electron microscopy (Morgan et al., 1994), cryoelectron
microscopy (Gilbert et al., 1999b), and homology models
(Rossjohn et al., 1998) have provided the only structural
information hitherto available. On the basis of its homology
with PFO (48% sequence identity and 60% sequence
similarity), PLY is thought to be a long rod-shaped molecule
comprising four domains with overall dimensions of 110 A˚
3 50 A˚ 3 30 A˚. Its secondary structure is mainly com-
posed of b-sheet motifs (Rossjohn et al., 1998), although
domain 3 is thought to contain several short a-helices.
The most conserved region of the CBTs is a sequence of
11 amino acids (ECTGLAWEWWR, also referred to as the
Trp-rich loop) at the base of the fourth domain, which is
thought to be responsible for membrane binding (Watson
et al., 1972). Biological and biophysical studies have shed
light on the speciﬁc mechanisms used by these toxins to bind
to (Jacobs et al., 1998, 1999; Nakamura et al., 1995; Tweten
et al., 1991) and further insert into (Palmer et al., 1996;
Shepard et al., 1998; Shatursky et al., 1999; Nakamura et al.,
1995; Heuck et al., 2000) cell membranes, and on their
cooperative self-organizing oligomerization (Morgan et al.,
1995, 1994) fostering pore formation and subsequent cell
lysis (Paton et al., 1993).
Two distinguishable but dependent processes, membrane
binding and protein oligomerization, collaborate in the pore-
formation process. A mechanism for CBT pore formation
consistent with accumulated biochemical and biophysical
data was proposed by Gilbert (2002) as follows: soluble
monomeric toxin binds to the membrane in a cholesterol-
dependent manner via the carboxy-terminal fourth domain.
Dimerization of bound toxin is the ﬁrst stage of either uni- or
bidirectional oligomerization which can terminate with as
many as 50 monomers forming a large (350 A˚ diameter;
Morgan et al., 1994) assembly on the cell surface. The PFO
prepore inserts into the membrane in a concerted action when
two groups of three small a-helices in domain 3 refold to
form two b-hairpins capable of forming the lumen of the
pore (Hotze et al., 2002). An alternative model for PFO pore
formation has been proposed by Rossjohn et al. (1997), in
which toxin insertion precedes pore formation. As yet, equiv-
alent data for PLY remain to be acquired.
The inhibition of thiol-activated pore-forming toxins by
preincubation with cholesterol reported in the early 1970s by
Watson et al. (1972) provided the ﬁrst evidence that this
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major constituent of eukaryotic cell membranes could be the
receptor for this family of toxins (see Duncan and Schlegel,
1975; Prigent and Alouf, 1976; Johnson et al., 1980, or for
a more recent article, Morgan et al., 1996). Preincubation
with cholesterol was thought to saturate all available binding
sites on the toxin, thwarting the further binding of the protein
with the cell membrane. That these CBTs do not attack
bacterial cell membranes (which contain ergosterol rather
than cholesterol in their membranes) was also evidence in
support of the above hypothesis. More recent studies
focusing on the effects triggered by membrane binding (for
example, monitoring cytokine expression and release of IL-
1) of LLO preincubated with cholesterol have suggested that
membrane association of the protein toxin-cholesterol com-
plex takes place but without any sign of cell lysis or pore
formation (Nishibori et al., 1996; Yoshikawa et al., 1993;
Sibelius et al., 1996). Further evidence supporting these
results has been provided by Jacobs et al. (1998), who used
immunoblot analysis and ﬂow cytometry to study the
binding and pore formation of LLO, demonstrating that pre-
incubation of LLO with cholesterol does not inﬂuence the
binding of this toxin to the cell membrane, but does affect
the polymerization process leading to pore formation. In this
article we present new results that further clarify the role
played by cholesterol as the putative receptor for cholesterol-
binding toxins in general and PLY in particular.
The lack of hydrophobic patches identiﬁable on either the
PLY homology model surface or its domain interfaces was
at ﬁrst surprising, since they constitute a common mecha-
nism for membrane disruption (Tweten, 1995; Alouf and
Geoffroy, 1991). Instead a novel mechanism was proposed
by Rossjohn and colleagues (Rossjohn et al., 1997, 1998;
Gilbert et al., 1999b). According to this mechanism, binding
to cholesterol displaces the Trp-rich motif from its original
position, which results in the formation of a hydrophobic
dagger that inserts into the membrane and may contribute
to membrane disruption. Alternatively, it has been suggested
that monomeric PLY would just sit on the cell membrane
(Ramachandran et al., 2002), triggering its destabilization,
and that the cooperative effect of further protein oligomer-
ization may ﬁnally foster membrane disruption, after pore
formation (Bonev et al., 2001).
Several ﬂuorescence studies with liposomes as model
membranes have been carried out in order to gain un-
derstanding of the binding-insertion mechanisms used by
CBTs. Nakamura et al. (1995) found that the tryptophan
ﬂuorescence intensity of PFO changed when the toxin
inserted into cholesterol-containing liposomes. In a more
recent article, Shepard et al. (1998) have monitored the
changes in the PFO Trp ﬂuorescence maximum upon
membrane binding and insertion, and have found a ﬂuores-
cence blue shift which indicates (Vivian and Callis, 2001)
that the environments of the Trp residues becomes more
nonpolar. If the overall Trp ﬂuorescence emission is
attributed to the Trp residues in the Trp-rich loop, this
indicates that this loop is moving from a polar to
a hydrophobic environment upon binding/insertion. In
addition, Heuck et al. (2000) have studied the changes in
PFO Trp ﬂuorescence upon binding to cholesterol-contain-
ing liposomes as a function of cholesterol concentration.
Based on these measurements, the authors propose a pore-
formation mechanism which comprises the following steps:
1), domain 4 superﬁcially binds to the membrane and ﬁnds
its ﬁnal position without being deeply embedded into the
membrane core; 2), in response to the binding of domain 4,
domain 3 undergoes a conformational change and inserts
into the membrane; and 3), it then acts to foster oligo-
merization and further pore-formation. Interactions of do-
mains 3 and 4 with the membrane are reported to be strongly
dependent on the concentration of cholesterol in the
liposome membrane.
More recently, Kelly and Jedrzejas (2000b) investigated
the characteristics of binding between a water-soluble
cholesterol analog (ws-chol) and PLY in solution, and found
differences in the CD spectra, hydrodynamic properties, and
Trp ﬂuorescence of the ws-chol-PLY complex with respect
to monomeric PLY. However, the interaction of ws-chol
with PLY may be completely different from that of true
cholesterol because of signiﬁcant structural differences (Fig.
1) between the two ligands. Therefore the results of Kelly
and Jedrzejas might not be truly relevant to the understand-
ing of the role of cholesterol in CBT pore-formation mech-
anisms.
Small-angle neutron scattering data have provided an
insight into the pore-formation mechanism of PLY (Gilbert
et al., 1999a, 1998). Different components of biological
systems possess different neutron scattering lengths, which
depend on their atomic composition and volume. The
scattering lengths of hydrogen and deuterium are very dis-
similar, 6.7 fm and 3.7 fm, respectively. By mixing ap-
propriate ratios of hydrogenated (light) and deuterated
(heavy) water, it is possible to match the scattering lengths
of different components of a biological system, making them
‘‘invisible’’ and enabling an experiment to focus on visible
components (see e.g., Byron and Gilbert, 2000). In the
experiments performed by Gilbert and co-workers, PLY was
chemically derivatized with dithionitrobenzoic acid to co-
valently label the only cysteine residue in PLY (Cys-428)
with a thionitrobenzoic (TNB) acid moiety. PLY-TNB
retained the ability to bind to the phospholipid membrane
but lacked the ability to oligomerize (Gilbert et al., 1999a),
conﬁrming that the processes of cell binding and oligomer-
ization are functionally separate. Derivatization was reversed
by the addition of dithiothreitol (DTT) in situ, after which
partial protein activity was restored.
The surface of phosphatidylcholine/cholesterol/dicetyl
phosphate liposomes has been shown to thicken after
addition of PLY-TNB, which has been interpreted as being
due to the binding of PLY-TNB monomers to the liposomal
surface without forming any pores (Gilbert et al., 1999a). In
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contrast, the surface of the liposomes thins when attacked by
wild-type (WT) PLY, clear evidence of the pore-formation
process taking place. The same thinning was observed after
addition of DTT to the sample containing liposomes and
PLY-TNB, which demonstrated that the thinning was due to
pore formation.
MATERIALS AND METHODS
Materials
Phosphatidylcholine (L-a-phosphatidylcholine from frozen egg yolk, purity
by TLC: 99%), dicetyl phosphate, cholesterol, ergosterol, lanosterol, and
deuterated water (99.9%) were from Sigma. Deuterated cholesterol (24, 24,
25, 25, 26, and 26-D, 95% deuteration) was fromMedical Isotopes (Pelham,
NH).
Protein expression, puriﬁcation,
and derivatization
PLY was overexpressed in M15 E. coli, using a protocol described
elsewhere (Gilbert et al., 1998). Protein puriﬁcation was performed using
hydrophobic and ion-exchange columns on a BioCAD perfusion chroma-
tography workstation (Applied Biosystems). Protein purity (.90%) was
assessed by SDS PAGE under reducing conditions. The protein was
immediately derivatized after puriﬁcation using Ellman’s reaction in which
the only free thiol group in PLY at residue C428 is reacted with
dithio(bis)nitrobenzoate to produce pneumolysin-thionitrobenzoate, i.e.,
PLY-TNB (Gilbert et al., 1998).
Liposome manufacture
Liposomes were prepared using a modiﬁcation of a procedure described
earlier (Gilbert et al., 1998). The liposome mixture (phosphatidylcholine/
sterol/dicetyl phosphate in a molar ratio 10:x:1, where sterol is either
cholesterol or ergosterol and x ranges from 0 to 10) was ﬁrstly dissolved in
a 1:1 (v/v) chloroform/methanol solution. For neutron reﬂectivity experi-
ments the molar concentration of cholesterol was the same as that of
phosphatidylcholine (i.e., x was 10). The absolute molar concentration was
such that when dissolved in the ﬁnal volume of aqueous buffer the solution
had a total lipid plus cholesterol molarity of 2 mM. The solution was then
dried under nitrogen and resuspended in CHB (50 mM NaH2PO4 and 200
mMNaCl, pH 4.8). Finally, the lipid solution was vortexed, sonicated (using
a bath sonicator at 45C for 45 min), repeatedly extruded through 0.2 mm
ﬁlters and centrifuged for 20 min at 3000 g. The liposomes were determined
to be spherical with an average size of 50 6 10 nm by dynamic light
scattering using a DynaPro MS800 single-angle detector instrument (Protein
Solutions, Lakewood, NJ). Two different types of cholesterol were
employed: standard hydrogenated and deuterated cholesterol (24, 24, 25,
25, 26, and 26-D; from Medical Isotopes, Pelham, NH).
Activity assays
PLY activity was assayed using a hemolytic assay (Walker et al., 1987).
50 ml of PBS buffer (125 mMNaCl, 1.5 mM KH2PO4, 8 mMNa2HPO4 and
2.5 mM KCl, pH 7.6) were loaded into the cells of a 96-well plate.
FIGURE 1 Structures of cholesterol
(the cell-surface receptor for pneumo-
lysin), water-soluble cholesterol, ergos-
terol, and lanosterol molecules.
Role of Cholesterol in PLY Activity 3143
Biophysical Journal 86(5) 3141–3151
Cholesterol/PLY solutions were prepared using a 7 mM PLY stock solution
in PBS and stock cholesterol, ergosterol and lanosterol solutions in 100%
ethanol. The samples were then vortexed and incubated for 5 min. Samples
to be assayed were loaded into the ﬁrst cell of each row and double-diluted
across the plate so that the ﬁrst column contained the more concentrated
sample and the last column contained the most dilute. 1 ml of whole sheep
blood was centrifuged and its pellet resuspended in 20 ml of PBS buffer and
then loaded (50 ml) into each well. Lastly, the plate was incubated at 37C
for 30 min. The red blood cells that are not lysed sink to the bottom of the
well and form a clear red dot in an otherwise transparent solution. On the
other hand, the lysed cells release their hemoglobin, giving the solution a red
color that provides a way of monitoring the protein lysing activity.
Hemolytic units (HU) were expressed as the reciprocal of the dilution at
which 50% lysis was observed.
Fluorescence
Fluorescence spectra were taken at room temperature (20C) using
a SpectraMax (Molecular Devices, Sunnyvale, CA) ﬂuorimeter. Tryptophan
residues were excited at a wavelength of 290 nm, and their ﬂuorescence
emission scanned from 300 to 520 nm. The ﬂuorescence emission intensity
was taken from the maximum of the spectra recorded for the different
cholesterol/PLY ratios (between 350 and 340 nm). The protein was used at
an initial concentration of 7 mM in PBS.
Neutron reﬂectivity experiments
Specular neutron reﬂectivity studies were performed on the SURF
reﬂectometer at the ISIS spallation neutron source, Rutherford Appleton
Laboratory (Didcot, UK). A standard instrument conﬁguration was used and
data collection and reduction proceeded as described by Penfold (1991) and
Penfold et al. (1987). Samples were housed in a solid/liquid cell (fully
described by Marsh et al., 1999). The silicon block through which the
neutrons travel is a single polished crystal of size 25 mm 3 51 mm 3 127
mm, presenting a [111] plane to the adsorbed liquid. The silicon block
surface facing down into the trough was cleaned by immersion into a mixture
of 90% (v/v) sulphuric acid and 10% hydrogen peroxide heated to 100C for
10 min. This procedure generated an extremely hydrophilic SiO2 layer on
the surface of the block that was assessed by its ability to retain a layer of
water when inclined vertically.
Solvents of three different neutron scattering length densities (or
contrasts) were used. The contrast is the result of the large difference in
neutron scattering length density between deuterium and hydrogen (see
above). Using a combination of deuterated and protonated solvent, different
contrasts can be obtained that give different reﬂectivity proﬁles whereas the
interface remains unchanged. The contrast solvents used were: PBS buffer
made with 100% D20; PBS buffer made with 100% H20; and PBS buffer
made with 42.3% (w/v) D20, which has the same neutron scattering length
density as the silicon substrate. The calculated scattering length densities of
the three solvents are 6.35 3 106 A˚2, 0.56 3 106 A˚2, and 2.07 3
106 A˚2, respectively.
RESULTS
The hemolytic activity of PLY is inhibited
by cholesterol, partially by ergosterol
but not by lanosterol
Cholesterol and coprostenol have been shown to be equally
effective in inhibiting toxin activity, whereas cholestanol and
coprostenol are slightly less efﬁcient (Smyth and Duncan,
1978). The presence of an a-OH group on the sterol C-3
atom (Fig. 1) is essential for its inhibiting activity, whereas
other compositional changes have been shown to reduce its
effectiveness (see Smyth and Duncan, 1978). The structure
of ergosterol is only slightly different from that of cholesterol
(the out-of-plane angle of a-OH, and a hydrogen atom
missing from C-8) whereas lanosterol differs more in its ring
structure. More different still is water-soluble cholesterol
(Kelly and Jedrzejas, 2000a), especially in the region of its
polar head.
The inhibition of PLY by these sterols was investigated
using a hemolytic assay (Walker et al., 1987), the results of
which are summarized in Table 1. Derivatization of PLY
with TNB abolished its measurable activity. Twenty-ﬁve
percent of WT activity could be restored by the addition of
DTT. The sterols in this assay were solubilized in 10% (v/v)
ethanol (EtOH). Neither EtOH nor EtOH plus cholesterol
lysed red blood cells. The activity of PLY was unaffected by
EtOH but was completely abolished by cholesterol.
Ergosterol reduced the toxin activity by 50%, whereas
lanosterol was a completely ineffective inhibitor.
The functional stoichiometry of the cholesterol-
PLY complex is 1:1
A series of samples with molar ratios of cholesterol/PLY
ranging from 0.01 to 200 was prepared and incubated for 30
min at 37C. The activity of the toxin in the different
solutions was monitored using a hemolytic assay (described
in Materials and Methods). In control ﬂuorescence experi-
ments we titrated PBS buffer with cholesterol so that the ﬁnal
concentration of sterol was sufﬁcient to give an increase in
light scattering signal (during ﬂuorescence experiments, data
not shown) providing evidence of micelle (or cholesterol
aggregate) formation. All subsequent protein titration ex-
periments with cholesterol were performed under conditions
for which light scattering was negligible. We therefore as-
sume that cholesterol was largely monomeric in our studies.
Fig. 2 shows the toxin normalized activity (normalized HU)
as a function of cholesterol/PLY molar ratio (hereafter, r) for
TABLE 1 Results from hemolytic assays with different
sterol inhibitors of PLY activity
Buffer PLY
PLY-
TNB DTT EtOH Chol Ergo Lano
% WT
activity
3 NA
3 3 100
3 3 NA
3 3 3 25
3 3 NA
3 3 3 NA
3 3 3 100
3 3 3 3 NA
3 3 3 3 50
3 3 3 3 100
NA, no activity; Chol, cholesterol; Ergo, ergosterol; Lano, lanosterol.
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three parallel titrations. Each curve includes a sharp
transition from full activity (,r ¼ 1) to complete inhibition
(.r ¼ 1) implying that the functional stoichiometry of the
cholesterol/PLY complex is 1:1.
Cholesterol/PLY binding and stoichiometry
in solution
To investigate the binding of cholesterol to PLY in solution,
the tryptophan (Trp) emission ﬂuorescence was monitored
as the cholesterol/PLY molar ratio was varied. PLY and
cholesterol stock solutions were used as before. Trp
ﬂuorescence was excited at 290 nm and ﬂuorescence
emission spectra were measured between 300 and 650 nm.
Fig. 3 shows typical Trp emission ﬂuorescence spectra at
different cholesterol/PLY molar ratios between 0:1 and 1:1.
Six of the eight Trp residues in PLY are located in domain 4
(according to the homology model; Rossjohn et al., 1998).
Of these, three are in the solvent-exposed Trp-rich loop,
implicated in cholesterol-mediated membrane binding. Only
one of the other three tryptophans in domain 4 is fully water-
exposed. The seventh Trp in PLY forms part of an a-helix at
the base of domain 3 and the eighth is positioned at the top of
domain 1, although neither of these tryptophans is solvent-
exposed in the model. The ﬂuorescence maximum in Fig. 3
at 350 nm suggests that the ﬂuorescence is mainly produced
by Trp residues in a polar environment (see Vivian and
Callis, 2001), and thus can be mostly attributed to the Trp
residues in the Trp-rich loop, whereas ﬂuorescence from
buried tryptophans would have a maximum closer to 320
nm. The signiﬁcant blue shift (10 nm) in the ﬂuorescence
maximum resultant upon an increase in cholesterol concen-
tration implies that the Trp environment becomes more
nonpolar upon addition of cholesterol, consistent with its
binding to the sterol.
Fig. 4 shows the change in normalized Trp ﬂuorescence
emission at 350 nm as the molar concentration of cholesterol
increases. The increase in ﬂuorescence emission indicates
again that the Trp environment becomes more nonpolar.
From the binding curve, it is possible to establish that the
stoichiometry of the cholesterol/PLY complex is 1:1, in
agreement with the functional stoichiometry measured via
hemolytic assay (above). The dissociation binding constant
(Kd) for the cholesterol/PLY complex was estimated to be
4006 100 nM by ﬁtting a one-binding-site model to the data
(y ¼ Bx/Kd 1 x, where y is the normalized ﬂuorescence, x is
the molar cholesterol concentration, and B a normalizing
constant). As a control for this study, PLY was titrated with
ethanol (using the same injection volumes as with choles-
terol): no change in the Trp ﬂuorescence emission was
observed; titration of PBS buffer with cholesterol under the
same experimental conditions showed no ﬂuorescence
FIGURE 2 Normalized activity (normalized HU) of PLY as a function of
the cholesterol/PLY molar ratio. A sharp transition in the toxin activity is
seen when the molar concentration of cholesterol equals PLY molar
concentration. The three symbols (and their corresponding b-spline
interpolations) are triplicate measurements of the same data.
FIGURE 3 Typical tryptophan emission ﬂuorescence spectra as the
cholesterol/PLY molar ratio increases from 0:1 to 1:1.
FIGURE 4 Tryptophan emission ﬂuorescence at 350 nm as a function of
cholesterol/PLY molar ratio. Cholesterol-binding saturation is reached at
a cholesterol/PLY molar ratio of 1:1, and the estimated binding constant is
400 6 100 nM. Solid line shows ﬁt to the data using a one site-binding
equation (see text for details).
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signal. We conclude from these cholesterol titration experi-
ments that cholesterol is able to bind to PLY in solution with
an estimated binding constant of 4006 100 nM. In addition,
the Trp emission ﬂuorescence peak shows a blue shift
indicating that the environment of the tryptophans involved
in cholesterol binding becomes more nonpolar upon
cholesterol binding.
Are there more cholesterol-binding motifs in PLY?
Ohno-Iwashita and colleagues determined that there are two
cholesterol-containing binding sites for PFO in the mem-
branes of sheep and human erythrocytes (Ohno-Iwashita
et al., 1988), one with lower and the other with higher
afﬁnity. In our solution experiments we determined that the
stoichiometry of the cholesterol-PLY complex in solution is
1:1. In the same experiments we estimated the binding
constant to be 4006 100 nM, which is in agreement with the
value measured previously by Ohno-Iwashita and colleagues
for the low afﬁnity binding site of PFO (Ohno-Iwashita et al.,
1988) when bound to human erythrocytes. If different forms
of cholesterol are bound by PFO and, by analogy, PLY, do
these toxins therefore have more than one cholesterol-
binding site? 21% of residues 126–354 of PLY are identical
to the human-brain acid-soluble protein 1 (BASP1), also
known as neuronal axonal membrane protein (NAP-22,
GenBank accession number 6686256; Swissprot accession
number P80723). The pairwise alignment between the two
proteins shown in Fig. 5 reveals that NAP-22 is homologous
with a large section of domain 1, 12 residues in domain 2,
and all of domain 3 of PLY. These are mapped onto the
homology model of PLY (based on PFO; Rossjohn et al.,
1998) in Fig. 6. The alignment requires the introduction of
only two single residue gaps in the NAP-22 sequence and the
distribution of homology throughout the sequences is
remarkably uniform. NAP-22 is a neuronal protein found
localized on the inner leaﬂet of raft domains. Its ability to
sequester cholesterol-rich domains is thought to be linked to
its N-terminal myristoylation (Epand et al., 2001), although
the myristoyl residue is probably more important for
membrane insertion whereas the protein residues determine
the interaction with cholesterol (Epand et al., 2002). The N-
myristoylation sequence of NAP-22 (Fig. 5) overlaps with
the cholesterol recognition/interaction sequence proposed by
Terashita et al. (2002). Six of the 15 residues in PLY that
align with this putative cholesterol recognition/interaction
sequence are at least 90% identical with the corresponding
NAP-22 sequence. Are there two cholesterol-binding/in-
teraction motifs in PLY? Our tryptophan ﬂuorescence data
indicate the formation of a 1:1 stoichiometric complex
between PLY and cholesterol, in apparent conﬂict with this
hypothesis. However, these measurements were performed
in solution: perhaps the two binding events are observed only
upon interaction of PLY with membranes, as originally
described by Ohno-Iwashita et al. (1988).
The second, putative cholesterol-binding motif described
above overlaps with the epitope to which PLY-4, a mono-
clonal antibody capable of preventing oligomerization of
PLY bound to cells, binds (Fig. 5). Does oligomerization of
PLY, bound to cholesterol, drive the formation of lipid
microdomains in cell membranes? Does this second binding
motif recognize inner leaﬂet cholesterol (as in NAP-22)
whereas the Trp-rich motif in domain 4 has a higher afﬁnity
for outer leaﬂet sterol? Little is known either about the
mechanism through which NAP-22 sequesters cholesterol
into domains or about the structure of the protein itself. It is
not known whether NAP-22 self-associates either in the
presence or absence of cholesterol. Although secondary
FIGURE 5 An alignment of the
amino acid sequences of PLY and
NAP-22 generated using MULTALIN
(Corpet, 1988). The BLOSUM 62
matrix was used with a gap weight of
12 and a gap length weight of 2. Red
indicates homology $90%; the symbol
‘‘#’’ is any one of NDQEBZ. The
putative cholesterol-binding sequence
is underlined. The approximate location
of the PLY-4 epitope is represented by
italics. Sequence numbering refers
to the PLY sequence, as does the
domain numbering. Two secondary
structure predictions based on the
programs PROF (http://www.aber.
ac.uk/phiwww/prof/) and SAM (http://
www.cse.ucsc.edu/research/compbio/
sam.html) are shown for NAP-22. The
PROF prediction for PLY is shown for
comparison alongside the secondary
structure of the high-resolution homol-
ogy model (Fig. 6).
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structure prediction programs predict that NAP-22 comprises
either all random coil, or random coil plus helix, circular
dichroism studies show that the protein contains ;50%
b-structure (the rest being random coil apart from 7%
helix; Epand et al., 2001). Neither the predicted nor the
experimentally determined secondary structure of NAP-22 is
homologous with the predicted secondary structure of PLY
(Fig. 5). There are no proteins sufﬁciently homologous with
NAP-22 for which a high-resolution structure has been de-
termined. This precludes the prediction of a high-resolution
structure for NAP-22. The secondary structure content of
NAP-22 is insensitive to pH (between 7.4 and 4.5, close to
the pI of the protein) and remains essentially unchanged
upon addition of liposomes containing 40% cholesterol. This
is not so for PLY if its mode of action is largely the same as
for its homolog PFO, wherein monomer-monomer inter-
actions drive two groups of three small a-helices in domain
3 to refold to form two b-hairpins upon membrane insertion
(Shatursky et al., 1999; Hotze et al., 2002). However, such
a refolding event might bring the putative second choles-
terol-binding site into contact with the appropriate choles-
terol receptor within the membrane.
Interestingly, Epand et al. (2001, 2002) based their iden-
tiﬁcation of a putative cholesterol-binding motif on earlier
workbyLiandPapadopoulos (1998),whopostulatedauniver-
sal cholesterol-binding motif of the form -L/V-(X)1–5-Y-(X)1–5-
R/K-. This motif occurs four times in PLY (residues
11–17, 144–152, 240–244, and 327–337; see Table 2 and
Fig. 6), and in fact is not found in the position homologous
with the putative cholesterol receptor in NAP-22. The four
motifs are differentially conserved across the sequences of
16 cholesterol-binding toxins (Table 2), PLY being the
only toxin in the list with all four motifs. PFO has two of the
four motifs. In fact, a total of 17 such motifs can be identiﬁed
in the list of 16 CBT sequences: some motifs are found only
in one protein (e.g., Motif 2 in Table 2 occurs in only one of
the six sequences, PLY), whereas others are found in many
(e.g., Motif 1 in Table 2 occurs in nine of the 16 sequences).
The questions raised above have not been addressed in this
article; instead, they have come to light during the course of
our investigation on the mode of interaction of PLY with
cholesterol. In future studies we hope to go some way toward
exploring the possibility of additional cholesterol-binding
motifs in PLY.
Neutron reﬂectivity experiments
Small-angle neutron scattering studies of the effect of PLY
on model membranes, in the form of liposomes, have been
described by Gilbert et al. (1999a). The liposome surface was
shown to thicken after addition of PLY-TNB, which has
been interpreted as being due to the binding of PLY-TNB
monomers. By contrast, addition of WT PLY was shown to
thin the liposomal surface, providing clear evidence of the
pore-formation process that was taking place. The same
thinning was observed upon addition of DTT to the sample
containing liposomes and PLY-TNB, which accordingly
conﬁrmed that the thinning was due to pore formation. The
authors proposed that changes in the structure of the
membrane upon binding of monomeric PLY increase the
efﬁciency of oligomerization—which, accordingly, triggers
pore formation.
In this article we report a specular neutron reﬂectivity
(NR) experiment performed to obtain additional informa-
tion on the mechanism of interaction of PLY with model
membranes. Specular reﬂectivity experiments are sensitive
to the difference in neutron scattering density between re-
gions of sample in the direction perpendicular to the surface
of the sample, and therefore should be sensitive to changes in
the structure of the bilayer due to the presence of the PLY.
The wavelength of the cold neutrons used in the NR study (a
few tenths of a nanometer) determines the length scales
probed by the experiment. Typically NR is sensitive to
structural features perpendicular to the plane of the sample
FIGURE 6 The homology model of PLY (Rossjohn et al., 1998) with the
region spanning the NAP-22 homology shown in red. Residues $90%
homology are shown in cyan; those corresponding to the four putative
cholesterol-binding motifs are in purple. The cholesterol-binding toxin,
conserved undecapeptide (to which cholesterol is thought to bind), is in
green.
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with length scales ranging from a few A˚ to 500 A˚. Neutrons
are particularly suited to studying organic ﬁlms because their
penetration power is larger than, for example, x rays, and so
they are able to provide data on buried interfaces.
Below the adsorbing block surface is a PFTE base block
from which a section has been cut to act as a trough
containing the liquid (in this case, solutions of liposomes).
The neutrons enter through one of the block faces and are
reﬂected from the silicon/liquid interface. If the difference in
neutron scattering length density at successive interfaces is
sufﬁcient, the technique will be sensitive to the thickness and
composition of the layers comprising the sample. First, the
silicon-oxide layer was characterized by measuring the
reﬂectivity proﬁle of the silicon block with the three contrast-
matched liquids (see Materials and Methods). Using a one-
layer model, the thickness of the silicon oxide was found to
be 86 3 A˚ with a scattering length density (SLD) of 3.41 3
106 A˚2 and a roughness of 5 A˚. This was then ﬁxed for all
the ﬁts subsequently performed for the more complex
reﬂectivity data.
We were interested in characterizing the main features of
the bilayer and in particular, differences in the bilayer
structure due to the presence of PLY. After characterization
of the SiO2 layer, a 2 mM SH liposome solution (;50 ml)
was poured into the trough. Once in contact with the
hydrophilic SiO2 layer, the liposomes collapse and give rise
to a unilamellar phospholipid bilayer. This bilayer was
characterized by measuring the neutron reﬂectivity proﬁles
at three contrasts. We ﬁtted ﬁrst the proﬁles with a one-layer
model. At the three contrasts used (the case of D2O is shown
in Fig. 7) we measured the bilayer thickness to be 366 5 A˚,
with an SLD that changes depending on the contrasts used.
For the D2O case shown in Fig. 7, the SLD of the layer was
2.12 3 106 A˚2. This value is compatible with the value
found by Johnson et al. (1991). The roughness of the layer
was 6 A˚. The values of the SLDs for the three contrast-
matched liquids are consistent in all three cases with 30% of
the liquids penetrating the bilayer, considering that the SLD
of the bilayer is 0.2 3 106 A˚2. This is compatible with
ﬁndings of others (Charitat et al., 1999; Johnson et al., 1991).
An 8 A˚-thick layer of water was included in the ﬁt with SLD
depending on the percentage of D2O in the buffer. We also
performed a more reﬁned ﬁt to the data with a more
complicated model to take into account the slightly different
SLD of tail and head layers. Although we could obtain
higher quality ﬁts in some cases, these did not change the
main results of our ﬁts: the total thickness of the bilayer and
the amount of water in it. To properly discern the different
structures (water, tails, and heads) we will need to perform
more experiments. The goal of our experiment was to
determine the structure of the bilayer after the insertion of the
toxin, so we have used a one-layer model for the bilayer in
our ﬁt (Fig. 8). When the bilayer contained deuterated
cholesterol we observed that the total thickness of the bilayer
was 42 6 4 A˚ with a higher SLD owing to the deuteration.
Finally, the derivatized toxinwas addedwithDTT (to aﬁnal
concentration of 60 mg/ml) to the trough and the new
reﬂectivity proﬁles were measured at the same contrasts as
before (Fig. 7). Here the goal was to observe possible changes
in the bilayer structure that may in turn give an insight into the
penetration of the bilayer by the toxin. It is important to stress
that we need to ﬁt NR data using a model, and therefore some
assumptions about the structure of the system have to be
made. We have ﬁtted the system using a two-layer model for
the bilayer. The thicknesses were 22 A˚ and 20 A˚, with
a roughness of 7 A˚, for the D2O case with an SLD of 1.4 3
106 A˚2 for the ﬁrst layer and 2.6 3 106 A˚2 for the
second layer. The thicknesses of the layerswere similar for the
other contrasts. The calculated SLD of PLY (discounting
exchange of protons for deuterons) is 3.25 3 106 A˚2, thus
we interpret the two layers as follows: the second (outer) layer
has an elevated SLD because toxin has inserted into the
TABLE 2 Conservation of the four 4 putative cholesterol-binding motifs across 16 cholesterol-binding toxins
Motif 1 Motif 2 Motif 3 Motif 4
S. pyogenes SLO L..NY LPARTQY VSNVAYGR YTSVFLK
S. equisimilis SLO L..NY LPARTQY VSNVAYGR YTSVFLK
S. canis SLO L..NY LPARTQY VSNVAYGR YTSVFLK
Alveolysin L..NYNR LPARLQY VSNVAYGR YTSVFLK
Tetanolysin L..SYNR LPARTQY VSNVAYGR YTTTFFK
Perfringolysin O L..SYNR LPARTQY VSNVAYGR YTSVFLK
Novyilisin L..SYNR LPARTQY VSNVAYGR YTSVFLK
Cereolysin L..TY LPARMQY VSNVAYGR YTSTFLK
Pneumolysin LAMNYDK VPARMQYEK VAYGR L..PISYTTSFLR
Intermedilysin L..QYDK VPARMQY VSNVSYGR V..PISYTTSFVK
Suilysin L..TY L....QY VSSVSYGR V..PISYSTNFVK
Listeriolysin O L..DYNK Y VAYGR V..PIAYTTNFLK
Seeligerilysin O L..NYDK Y VAYGR V..PISYTTNFLK
Ivanolysin O L..DYDK Y VAYGR V..PIAYTTNFLK
Pyolysin L..KY Y VSYGR V..PVSYAVNFLK
Septicolysin O YTFVGR   LFFLVGYIVLRAK
SLO, Streptolysin O; —, signiﬁes that the motif is completely absent.
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bilayer to a depth that corresponds to the thickness of this
layer leaving the ﬁrst (inner) layer free of toxin. Again, we
stress that in the NR technique, a model must be used to ﬁt the
data, and we have considered the simplest one.
More experiments are needed to conﬁrm these observa-
tions, and to further investigate the interaction of the toxin
with bilayer, its level of penetration, and the formation of
pores. Moreover, additional work is required to determine
whether the deuterated cholesterol layer inside the lipid bi-
layer changes position after toxin insertion.
DISCUSSION
The main objective of this work was to study the interaction
of cholesterol and PLY in solution. We determined the
functional stoichiometry of the complex to be 1:1 by using
a technique based on hemolytic assays. By the same means,
we studied the speciﬁcity of the cholesterol-PLY interaction
and demonstrated that sterols very similar to cholesterol are
not able to efﬁciently inhibit PLY function. This implies that
cholesterol perhaps cannot be replaced by other similar
sterols to study its speciﬁc interaction with PLY, as was done
in previous studies (Kelly and Jedrzejas, 2000a,b). Indeed
Kelly and Jedrzejas observed saturation of ws-cholesterol
binding to PLY at a PLY/ws-cholesterol molar ratio of
;1:3000, far in excess of the saturation point we have
measured for standard cholesterol.
In addition, we employed tryptophan emission ﬂuores-
cence spectroscopy to conﬁrm the 1:1 stoichiometry of the
cholesterol-PLY complex. In the same experiments we
estimated the binding constant to be 400 6 100 nM, in
agreement with value measured previously by Ohno-
Iwashita and colleagues for PFO (Ohno-Iwashita et al.,
1988). That the tryptophan environment becomes more
nonpolar upon binding cholesterol, reinforces the hypothesis
that cholesterol interacts with PLY by speciﬁcally binding to
the highly conserved Trp-rich loop. However, Ohno-
Iwashita and colleagues determined that there are two
cholesterol-containing binding sites for PFO in the mem-
branes of sheep and human erythrocytes (Ohno-Iwashita
et al., 1988). The high-afﬁnity (Kd  2 nM) site comprises
;3% of the total binding sites, whereas the majority have
a 100-fold lower afﬁnity (Kd  220 nM). Are we measuring
an average of these afﬁnities for PLY? What is it about the
binding sites for PFO that modulates the apparent binding
afﬁnity? Ohno-Iwashita et al. speculated that the accessibil-
ity of the toxin to the cholesterol in the high-afﬁnity binding
sites must not be restricted in the same way as for the low-
afﬁnity sites. Perhaps the high-afﬁnity binding site is outer-
leaﬂet cholesterol, whereas inner-leaﬂet cholesterol forms
the low-afﬁnity site—the asymmetry of the leaﬂets account-
ing for the difference in number of high- and low-afﬁnity
sites. Alternatively, the preferential localization of glyco-
sphingolipids and sphingomyelin within the outer leaﬂet of
lipid rafts could perturb access to cholesterol within raft
domains: the high- and low-afﬁnity sites may correspond to
free and lipid-raft cholesterol, respectively. A further
alternative model (Gilbert, 2002) ascribes the low-afﬁnity
binding site to cholesterol monomers dissolved in the
membrane, whereas the high-afﬁnity site is a tail-to-tail
transbilayer cholesterol dimer. In the titration experiments
reported here we observed essentially a low-afﬁnity binding
event, consistent with binding to cholesterol monomers.
FIGURE 7 Neutron reﬂectivity curves for the bilayer adsorbed on the
silicon in the presence (s) and absence (h) of activated toxin. Only the D2O
contrast is shown for clarity. The solid lines are the ﬁts to a model described
in the text.
FIGURE 8 Neutron reﬂectivity proﬁles for the hydrogenated bilayer
adsorbed onto the silicon-oxide substrate at the three contrasts: D2O (s),
H2O (h), and 43% D2O (,). The proﬁles were ﬁtted with a one-layer model
for the bilayer for simplicity, as described in the text. The solid lines are ﬁts
to the data. A thin water layer was included on top of the silicon oxide during
the ﬁts, as observed by Charitat et al. (1999) and Johnson et al. (1991).
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Finally, we used neutron reﬂectivity to investigate the
interaction of PLY with a phospholipid bilayer. PLY was
shown to interact with the membrane by producing an
effective change in the overall membrane thickness, by
altering its neutron scattering length density and by forming
a further layer of different scattering length density atop the
phospholipid bilayer.
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